Terms: = Breast cancer AND WHSC1, 7468, O96028, WHS, TRX5, REIIBP, NSD2, MMSET, MGC176638, KIAA1090, FLJ23286 AND Treatment
5 results:
1. The Association of Overall Annual Hospital Volume and Perioperative Outcomes following Free Flap breast Reconstruction.
Shammas RL; Ren Y; Thomas SM; Phillips BT; Hollenbeck ST; Greenup RA
Plast Reconstr Surg; 2021 Feb; 147(2):196e-206e. PubMed ID: 33565821
[TBL] [Abstract] [Full Text] [Related]
2. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of nsd2 degradation and suppression of nsd2-driven redox homeostasis.
Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
[TBL] [Abstract] [Full Text] [Related]
3. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract] [Full Text] [Related]
4. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
5. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
[TBL] [Abstract] [Full Text] [Related]
